Camrelizumab Plus Apatinib Successfully Treated a Patient with Advanced Esophageal Squamous Cell Carcinoma

• DOI: 10.2217/imt-2020-0197
• Publication Date: 2020-08-20T08:59:03Z
• Authors: Zheng Yan; Zhi-Hua Yao; Shu-Na Yao; Hai-Ying Wang; Jun-Feng Chu; Ming Song; Shuang Zhao; Yan-Yan Liu
• Keywords: Male; Esophageal Neoplasms; Pyridines; Antineoplastic Agents; Middle Aged; Antibodies, Monoclonal, Humanized; 3. Good health; 03 medical and health sciences; Treatment Outcome; 0302 clinical medicine; Humans; Drug Therapy, Combination; Esophageal Squamous Cell Carcinoma; Immunotherapy

Aim: Advanced esophageal squamous cell carcinoma (ESCC) is a lethal disease with poor response to conventional chemotherapy. Immunotherapy showed better activity than chemotherapy in late-line treatment. However, the rate and duration of response are far from satisfactory. The efficacy of an anti-angiogenic agent combined with immunotherapy for ESCC is unknown. Results: A patient with ESCC experienced disease relapse after chemo-radiotherapy. The disease progressed after combined chemotherapy. A combination regimen of the PD-1 inhibitor camrelizumab and the anti-angiogenic agent apatinib was administered. The patient achieved a PET/CT-confirmed durable complete response with mild toxicity. Conclusion: The PD-1 inhibitor combined with the anti-angiogenic agent is effective and safe for the treatment of ESCC. This regimen is worth investigation in clinical trials.